Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
N Engl J Med. 2021 10 21; 385(17):1627-1629.NEJM

Links

PMC Free PDF

Authors+Show Affiliations

Falsey AR
University of Rochester, Rochester, NY.
Frenck RW
Cincinnati Children's Hospital, Cincinnati, OH.
Walsh EE
University of Rochester, Rochester, NY.
Kitchin N
Pfizer Vaccine Research and Development, Hurley, United Kingdom nicholas.kitchin@pfizer.com.
Absalon J
Pfizer Vaccine Research and Development, Pearl River, NY.
Gurtman A
Pfizer Vaccine Research and Development, Pearl River, NY.
Lockhart S
Pfizer Vaccine Research and Development, Hurley, United Kingdom.
Bailey R
Pfizer Vaccine Research and Development, Hurley, United Kingdom.
Swanson KA
Pfizer Vaccine Research and Development, Pearl River, NY.
Xu X
Pfizer Vaccine Research and Development, Collegeville, PA.
Koury K
Pfizer Vaccine Research and Development, Pearl River, NY.
Kalina W
Pfizer Vaccine Research and Development, Pearl River, NY.
Cooper D
Pfizer Vaccine Research and Development, Pearl River, NY.
Zou J
University of Texas Medical Branch, Galveston, TX.
Xie X
University of Texas Medical Branch, Galveston, TX.
Xia H
University of Texas Medical Branch, Galveston, TX.
Türeci Ö
BioNTech, Mainz, Germany.
Lagkadinou E
BioNTech, Mainz, Germany.
Tompkins KR
Pfizer Vaccine Research and Development, Pearl River, NY.
Shi PY
University of Texas Medical Branch, Galveston, TX.
Jansen KU
Pfizer Vaccine Research and Development, Pearl River, NY.
Şahin U
BioNTech, Mainz, Germany.
Dormitzer PR
Pfizer Vaccine Research and Development, Pearl River, NY.
Gruber WC
Pfizer Vaccine Research and Development, Pearl River, NY.

MeSH

AdolescentAdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunization, SecondaryImmunogenicity, VaccineMiddle AgedSARS-CoV-2Young Adult

Pub Type(s)

Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34525276

Citation

Falsey, Ann R., et al. "SARS-CoV-2 Neutralization With BNT162b2 Vaccine Dose 3." The New England Journal of Medicine, vol. 385, no. 17, 2021, pp. 1627-1629.
Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021;385(17):1627-1629.
Falsey, A. R., Frenck, R. W., Walsh, E. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Bailey, R., Swanson, K. A., Xu, X., Koury, K., Kalina, W., Cooper, D., Zou, J., Xie, X., Xia, H., Türeci, Ö., Lagkadinou, E., Tompkins, K. R., ... Gruber, W. C. (2021). SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. The New England Journal of Medicine, 385(17), 1627-1629. https://doi.org/10.1056/NEJMc2113468
Falsey AR, et al. SARS-CoV-2 Neutralization With BNT162b2 Vaccine Dose 3. N Engl J Med. 2021 10 21;385(17):1627-1629. PubMed PMID: 34525276.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. AU - Falsey,Ann R, AU - Frenck,Robert W,Jr AU - Walsh,Edward E, AU - Kitchin,Nicholas, AU - Absalon,Judith, AU - Gurtman,Alejandra, AU - Lockhart,Stephen, AU - Bailey,Ruth, AU - Swanson,Kena A, AU - Xu,Xia, AU - Koury,Kenneth, AU - Kalina,Warren, AU - Cooper,David, AU - Zou,Jing, AU - Xie,Xuping, AU - Xia,Hongjie, AU - Türeci,Özlem, AU - Lagkadinou,Eleni, AU - Tompkins,Kristin R, AU - Shi,Pei-Yong, AU - Jansen,Kathrin U, AU - Şahin,Uğur, AU - Dormitzer,Philip R, AU - Gruber,William C, Y1 - 2021/09/15/ PY - 2021/9/16/pubmed PY - 2021/10/27/medline PY - 2021/9/15/entrez SP - 1627 EP - 1629 JF - The New England journal of medicine JO - N Engl J Med VL - 385 IS - 17 SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/34525276/SARS_CoV_2_Neutralization_with_BNT162b2_Vaccine_Dose_3_ DB - PRIME DP - Unbound Medicine ER -